

1
2 **Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a**
3 **randomized placebo-controlled trial**

4
5 Prasanna Jagannathan^{1,2}, Jason R. Andrews^{1‡}, Hector Bonilla^{1‡}, Haley Hedlin^{3‡}, Karen B.
6 Jacobson¹, Vidhya Balasubramanian³, Natasha Purington³, Savita Kamble⁴, Christiaan R. de
7 Vries¹, Orlando Quintero¹, Kent Feng⁴, Catherine Ley¹, Dean Winslow¹, Jennifer Newberry⁵,
8 Karlie Edwards¹, Colin Hislop⁶, Ingrid Choong⁶, Yvonne Maldonado⁷, Jeffrey Glenn^{1,2}, Ami
9 Bhatt^{1,8}, Catherine Blish¹, Taia Wang^{1,2}, Chaitan Khosla⁹, Benjamin A. Pinsky^{1,10}, Manisha
10 Desai³, Julie Parsonnet¹, Upinder Singh^{1,2}

11 ¹ Department of Medicine, Stanford University, Stanford, CA, USA

12 ² Department of Microbiology and Immunology, Stanford University, Stanford, CA USA

13 ³ Quantitative Sciences Unit, Stanford University, Stanford, CA, USA

14 ⁴ Stanford Center for Clinical Research, Stanford University, Stanford, CA USA

15 ⁵ Department of Emergency Medicine, Stanford University, Stanford, CA, USA

16 ⁶ Department of Pediatrics, Stanford University, Stanford, CA, USA

17 ⁷ Eiger BioPharmaceuticals, Palo Alto, CA, USA

18 ⁸ Department of Genetics, Stanford University, Stanford, CA USA

19 ⁹ ChEM-H, Stanford University, Stanford, CA USA

20 ¹⁰ Department of Pathology, Stanford University, Stanford, CA USA

21 ‡ These authors contributed equally (listed alphabetically)

22 Correspondence to: Prasanna Jagannathan, Stanford University, 240 Pasteur Drive, Room 3456,

23 Stanford, CA 94305. prasj@stanford.edu; and Upinder Singh, Stanford University, 300 Pasteur

24 Drive, Suite 154, Stanford, CA 94305. usingh@stanford.edu.

25 **Word Counts:**

26 **Abstract: 197**

27 **Manuscript: 2317 (excluding methods)**

28

29 **Abstract**

30 Type III interferons have been touted as promising therapeutics in outpatients with coronavirus
31 disease 2019 (COVID-19). We conducted a randomized placebo-controlled trial in 120 patients
32 with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of
33 Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding (primary
34 endpoint) or symptoms (secondary endpoint, NCT04331899). In both the 60 patients receiving
35 Lambda and the 60 receiving placebo, the median time to cessation of viral shedding was 7 days
36 (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8
37 and 9 days in Lambda and placebo, respectively (HR 0.94; 95% CI 0.64 to 1.39). At enrollment;
38 41% of subjects were SARS-CoV-2 IgG seropositive; compared to placebo, lambda tended to
39 delay shedding cessation in seronegatives (aHR 0.66, 95% CI 0.39-1.10) and to hasten shedding
40 cessation in seropositives (aHR 1.58, 95% CI 0.88-2.86; p for interaction = 0.03). Liver
41 transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p =
42 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened
43 the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with
44 uncomplicated COVID-19.

45

46

47

48 Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome
49 Coronavirus 2 (SARS-CoV-2), has led to nearly 1 million deaths worldwide as of September
50 2020.¹ Although most infected patients display mild symptoms, even uncomplicated infections
51 can contribute to transmission to those with co-morbid conditions and other high risk groups,
52 increasing overall mortality.² With the unprecedented health and economic threats imposed by
53 COVID-19, therapeutics are urgently needed to shorten the duration of viral shedding, relieve
54 symptoms, and prevent hospitalizations..
55
56 Interferons (IFNs) are promising anti-SARS-CoV-2 therapeutics, given their importance in the
57 early response to viral infections.³ Innate immune sensing of viral nucleic acids leads to
58 production of type I (IFN- α , IFN- β) and type III (IFN- λ) IFNs that, after binding to their cognate
59 receptors, activate genes critical for host protection.⁴⁻⁶ SARS-CoV-2 encodes proteins that
60 suppress production of endogenous IFN⁷, and infection has been associated with markedly
61 reduced type I and type III IFN signaling⁸, particularly in patients with severe manifestations of
62 disease.^{9,10} Both type I and type III IFNs inhibit SARS-CoV-2 *in vitro*^{11,12}, suggesting potential
63 utility of exogenous IFN administration to aid in viral control and prevent disease progression. In
64 support of this hypothesis, recent trials in hospitalized COVID-19 patients have reported that
65 type I IFN administration may reduce the duration of viral shedding and symptoms.¹³⁻¹⁵
66
67 Whereas cognate receptors to type I IFNs are expressed ubiquitously, the receptor complex
68 (IL28R) for IFN- λ is expressed on only a few cell types, including epithelial cells in the
69 gastrointestinal and respiratory tracts.^{4,16,17} These cellular affinities have led investigators to use
70 this agent to target viral hepatitis^{18,19} and respiratory viral infections¹⁶. In a murine model of

71 influenza infection, IFN- λ treatment post-infection was associated with significantly lower
72 mortality compared to mice treated with IFN- α , and this was associated with lower influenza
73 viral loads²⁰. A pegylated form of recombinant IFN- λ , Peginterferon Lambda-1a (Lambda) has
74 been developed for the treatment of chronic viral hepatitis. Lambda, given weekly as 180 mcg
75 subcutaneous injections, has comparable antiviral efficacy and an improved tolerability profile
76 compared with type I IFN for the treatment of hepatitis²¹, likely due to its relatively limited
77 receptor distribution. In a murine model of SARS-CoV-2 infection, subcutaneous administration
78 of Lambda prophylactically or early after infection diminished SARS-CoV-2 replication in the
79 lower respiratory tracts of mice *in vivo*¹¹.

80

81 Lambda has thus emerged as a promising treatment candidate for SARS-CoV-2^{22,23} given a
82 plausible mechanism of action, the suppression of IFN activity by SARS-CoV2, and *in vitro* and
83 *in vivo* studies showing that IFN- λ administration can inhibit SARS-CoV-2 replication. To date,
84 no therapies have been approved for outpatients with mild to moderate COVID-19 disease. We
85 therefore conducted a randomized, placebo-controlled trial of Lambda for outpatients with
86 uncomplicated SARS-CoV-2 infection. We tested the hypothesis that a single, 180 mcg
87 subcutaneous injection of Lambda would be associated with a shorter duration of viral shedding
88 in comparison to a normal saline placebo injection.

89

90 **Results**

91 *Cohort Characteristics*

92 We enrolled 120 participants between April 25 and July 17, 2020, of whom 110 (91.7%)
93 completed 28 days of follow up (**Fig 1a**). The median age was 36 years (range 18-71), 50

94 participants (41.7%) were female, and 75 (62.5%) were Latinx ethnicity (**Table 1**). Eight (6.7%)
95 participants were asymptomatic at baseline. Of those with symptoms, the median duration of
96 symptoms prior to randomization was five days. The most common symptoms were fatigue,
97 cough, headache, and myalgias (**Table 1, Fig S1**). Only 13 (10.8%) participants had an elevated
98 temperature ($>99.5^{\circ}\text{F}$) at baseline; the median oxygen saturation was 98%.

99

100 *Baseline oropharyngeal viral RNA level and SARS-CoV-2 IgG serostatus*

101 The presence of SARS-CoV-2 RNA was assessed at baseline and at 8 follow-up visits using
102 oropharyngeal swabs, a Centers for Disease Control approved method for SARS-CoV-2
103 detection²⁴. This method was selected given the frequency of repeated assessments and improved
104 tolerability for participants compared with nasopharyngeal swabs. The median SARS-CoV-2
105 oropharyngeal viral PCR cycle threshold at enrollment was 30.3 (corresponding to a median viral
106 load of 4.4 Log₁₀ copies/ml), and did not differ significantly between groups (**Table 1**).

107

108 IgG antibody titers against the SARS-CoV-2 spike receptor binding domain (RBD) were
109 assessed at enrollment by enzyme linked immunosorbent assay.²⁵ At enrollment, 49 (40.8%)
110 participants were SARS-CoV-2 IgG seropositive. Baseline SARS-CoV-2 serostatus did not
111 significantly differ between groups (**Table 1**). The median duration of symptoms prior to
112 enrollment was significantly shorter in SARS-CoV-2 IgG seronegative vs. seropositive
113 participants (median [interquartile range [IQR]]: 3.5 [2.5-5] days vs. 5 [4-7] days, $P=0.0051$).

114 Seronegative participants also had significantly higher oropharyngeal viral RNA levels at
115 enrollment compared with seropositive participants (median [IQR] log₁₀ viral load 4.4 [2.5] vs.
116 2.0 [2.4]).

117

118 *Primary Virologic Analysis*

119 Of 120 enrolled participants, 60 were randomized to receive Lambda and 60 randomized to
120 receive placebo and included in the analysis. The median time to cessation of oropharyngeal
121 viral shedding was 7 days in both arms (95% CI 5-10 days for placebo vs 5-13 days for Lambda,
122 **Table 2**). There was no significant difference in the adjusted hazard ratio (aHR) for shedding
123 cessation between Lambda and placebo; participants in the lambda arm were 19% less likely to
124 cease shedding at any point during the study period compared to participants in the placebo arm
125 (aHR 0.81, 95% confidence interval [CI] 0.56 to 1.19; $p = 0.29$, **Fig 2A**.) Overall, 108
126 participants met the primary endpoint and were not censored. Because two participants, after
127 randomization, inadvertently were injected with the incorrect syringe, we also conducted an as-
128 treated analysis according to treatment actually received. Findings from an as-treated analysis
129 (aHR 0.83, 95% CI 0.56 to 1.21; $p = 0.33$) and an analysis performed in symptomatic patients
130 only (aHR 0.77, 95% CI 0.52 to 1.15, $p = 0.21$) were similar.

131

132 In exploratory analysis, seropositivity at baseline was associated with significantly hastened
133 shedding cessation. The median time to shedding cessation was 10 days in SARS-CoV-2 IgG
134 seronegative individuals vs. 3 days in seropositive individuals (95% CI 7-14 days for
135 seronegative vs 1-6 days for seropositive, aHR 2.65, 95% CI 1.74-4.03, $P < 0.001$, **Fig S2**).

136 Baseline serostatus also significantly modified the effect of treatment on time to shedding
137 cessation ($p = 0.03$). Among seronegative individuals, Lambda delayed shedding cessation
138 compared with placebo (aHR 0.66, 95% CI 0.39-1.10, **Fig 3a**). Among seropositive individuals,
139 Lambda hastened shedding cessation (aHR 1.58, 95% CI 0.88-2.86, **Fig 3a**).

140
141 Higher oropharyngeal viral RNA levels at baseline were associated with significantly delayed
142 shedding cessation (aHR 0.32 comparing baseline CT <30 vs baseline CT ≥30, 95% CI 0.21-
143 0.50, P<0.001, **Fig S3**). Although baseline oropharyngeal viral RNA levels did not significantly
144 modify the effect of treatment on time to shedding cessation (p=0.15), among individuals with
145 high baseline viral RNA levels, Lambda delayed shedding cessation compared with placebo
146 (aHR 0.51, 95% CI 0.26-1.04, **Fig 3b**). There was no difference in shedding cessation between
147 arms with low baseline viral RNA levels (aHR 0.95, 95% CI 0.60-1.52, **Fig 3b**). No other
148 baseline features of interest significantly modified the effect of treatment and the primary
149 outcome (**Table S1**).

150

151 *Secondary analyses*

152 No significant difference in time to resolution of symptoms (aHR 0.94; 95% CI 0.64 to 1.39; p =
153 0.76, **Fig 2B**) or sustained resolution of symptoms (aHR 0.92; 95% CI 0.60 to 1.41; p = 0.70)
154 was observed, nor did we find any significant difference in resolution of symptom complexes
155 (**Table 2, Fig S4**). Time to clinical progression was not significantly different between the two
156 arms (aHR 1.38; 95% CI 0.52 to 3.63; p = 0.52). Trajectory of viral RNA levels did not vary by
157 treatment arm (p=0.91, **Fig S5**) nor did viral RNA area under the curve (p = 0.95, **Table 2**).

158

159 *Adverse Events*

160 Twenty-five (42%) Lambda and 21 (35%) placebo participants experienced adverse events
161 (**Table 3**). Two serious adverse events (hospitalizations) were reported in each arm. Liver
162 transaminase elevations were more common in the Lambda vs. placebo arm (15 vs 5; p = 0.027).
163 Furthermore, we observed significant elevations in alanine transaminase levels from day 0 to day

164 5 among individuals randomized to Lambda, but not among individuals randomized to placebo
165 (Fig 4). However, there were no associated symptoms and lab abnormalities were not sustained.

166

167 Discussion

168 In this study of outpatients with uncomplicated SARS-CoV-2 infection, a single subcutaneous
169 injection of Lambda did not significantly reduce time to viral clearance or resolution of
170 symptoms compared with placebo. We recruited participants within 72 hours of diagnosis,
171 giving us an excellent opportunity to intervene early within the course of infection. We attained
172 excellent follow-up and retention, with few missed visits (<5%), and little missing data. Despite
173 these strengths and compelling preclinical data--i.e., a plausible mechanism of action, the
174 suppression of IFN activity by respiratory coronaviruses, and both *in vitro* and *in vivo* studies
175 showing inhibition of SARS-CoV-2 replication by IFN- $\lambda^{11,12}$ --this phase 2 trial yielded little
176 promise of efficacy at the tested dose and administration schedule. Lambda was well-tolerated,
177 with few adverse effects, though asymptomatic liver transaminase elevations occurred more
178 frequently in participants randomized to Lambda and are consistent with previous reports.^{21,26}

179

180 The lack of effect of Lambda was surprising given recently described *in vitro* data and benefits
181 seen in an *in vivo* model with early therapeutic and prophylactic administration¹². There are
182 several potential reasons for this lack of benefit. First, although we attempted to randomize
183 participants as soon as possible after the COVID-19 diagnosis was made, the median symptom
184 duration was 5 days at the time of randomization, and 40% of participants were already SARS-
185 CoV-2 IgG positive at enrollment. It is possible that earlier administration, or prophylactic
186 administration prior to established infection, would have been beneficial. Arguing against this,

187 we observed no evidence of benefit among SARS-CoV-2 seronegative individuals, who
188 presumably have been infected a shorter period of time. Second, a single, 180 mcg subcutaneous
189 injection of Lambda may not achieve adequate therapeutic levels of drug in the upper respiratory
190 epithelia. Consistent with this, a murine model of SARS-CoV-2 infection found that
191 subcutaneous administration of Lambda did not result in significant reductions of SARS-CoV-2
192 viral titers in upper respiratory epithelium.¹² It is possible that higher, or more frequent, dosing
193 may have been beneficial. However, subcutaneous doses greater than 180 mcg in humans are
194 limited by increasing drug toxicity, including significant liver transaminase elevations²¹. Finally,
195 IFN- λ has been shown to disrupt the lung epithelial barrier in mice, leading to worsened disease
196 course and increase susceptibility to bacterial superinfection^{27,28}. This may negate any positive
197 antiviral effects.

198
199 These data are in contrast to reports of benefits of Type I IFN in hospitalized COVID-19
200 patients. Subcutaneous IFN- β along with ribavirin and lopinavir/ritonavir was associated with
201 shortened duration of symptoms and viral shedding in hospitalized patients in Hong Kong¹⁴, and
202 a randomized clinical trial in England also suggest benefits of inhaled IFN- β for COVID-19.²⁹
203 Although both type I and type III IFN activate the same dominant JAK-STAT signaling
204 pathway⁶, inhibit SARS-CoV-2 *in vitro*^{10,11}, and have receptors on respiratory epithelia¹⁶, *in vivo*
205 activity and efficacy may differ⁶. A recent report found that inborn errors of Type I IFN
206 immunity, including autosomal recessive IFNAR1 deficiency, were enriched in patients with
207 life-threatening COVID-19 pneumonia³⁰. Furthermore, patients with COVID-19 pneumonia
208 were also more likely to have neutralizing auto-antibodies against type I, but not type III, IFNs³¹.

209 These data suggest the possibility that type I IFN administration may be more beneficial than
210 type III IFN in preventing adverse outcomes of SARS-CoV-2 infection.

211
212 Although there was some evidence that SARS-CoV-2 seropositivity at baseline modified the
213 effect of treatment on shedding cessation, the effect modification was in the opposite direction
214 than we had anticipated; Lambda appeared to prolong shedding relative to placebo among those
215 who were seronegative at baseline, and to shorten the duration of shedding among those who
216 were seropositive at baseline. Furthermore, Lambda also appeared to prolong shedding relative
217 to placebo among those with high baseline viral RNA levels. These findings should be
218 interpreted with caution for two reasons. First, these were exploratory analysis only and should
219 be considered hypothesis generating. Second, these observations defy biological plausibility
220 based on *in vitro* and animal model data.

221
222 The majority (62.5%) of participants in our study were Latinx, reflecting the high burden of
223 COVID-19 among the Latinx community in our surrounding communities.³² Minority
224 populations are disproportionately affected by COVID-19, with higher rates of infection and
225 deaths observed due to a multitude of socioeconomic and demographic factors.^{33,34} Attention has
226 recently been called to the relative absence of the most affected minorities in treatment trials^{35,36},
227 and we prioritized recruitment efforts to the Latinx community in our study.

228
229 The study did have a few limitations. We recruited both symptomatic and asymptomatic patients.
230 Asymptomatic patients contributed less to secondary outcomes since they presented with lower
231 viral RNA levels and could not contribute to analyses of symptom alleviation. However, these

232 patients represented <10% of the enrolled cohort. Additionally, despite a reported median
233 duration of symptoms prior to randomization of only 5 days, 40% of participants were already
234 seropositive at enrollment. Unpublished data from a Regeneron outpatient monoclonal antibody
235 study with similar study design (REGN-COV2) found similar rates of baseline SARS-CoV-2
236 IgG seropositivity (45%).³⁷ These data suggest that enrolling COVID-19 outpatients early in the
237 course of disease, before they develop an antibody response, may be challenging. Nonetheless,
238 we found no suggestion of benefit of Lambda in seronegative individuals. Finally, the median
239 time to cessation in the placebo arm was shorter than assumed in our sample size calculations,
240 potentially due to less severe disease in this population. However, our original sample size
241 estimates based on the number of events and median time to event were conservative; a shorter
242 time to cessation, keeping all other assumptions the same, increases the power to detect
243 differences between groups.

244

245 In conclusion, a single dose of subcutaneous Peginterferon Lambda-1a, while safe, neither
246 reduced time to cessation of viral shedding nor symptom duration in outpatients with
247 uncomplicated COVID-19 in this large, Phase 2, single-center study. Further investigation into
248 the therapeutic utility of type III interferons for COVID-19 in patients with severe illness or as a
249 prophylactic treatment are underway.

250

251

252 **Methods**

253 *Trial Design and Oversight*

254 We conducted a Phase 2, single-blind, randomized placebo-controlled trial to evaluate the
255 efficacy of Lambda in reducing the duration of viral shedding in outpatients. The trial was

256 conducted within the Stanford Health Care System. Adults aged 18-65 years with an FDA
257 emergency use authorized reverse transcription-polymerase chain reaction (RT-PCR) positive for
258 SARS-CoV-2 within 72 hours from swab to the time of enrolment were eligible for participation
259 in this study. Exclusion criteria included current or imminent hospitalization, respiratory rate >20
260 breaths per minute, room air oxygen saturation <94%, pregnancy or breastfeeding, history of
261 decompensated liver disease, recent use of interferons, antibiotics, anticoagulants or other
262 investigational and/or immunomodulatory agents for treatment of COVID-19, and prespecified
263 lab abnormalities. Full eligibility criteria are provided in the study protocol. The protocol was
264 amended on June 16th, 2020 after 54 participants were enrolled but before results were available
265 to include adults up to 75 years of age and eliminate exclusion criteria for low white blood cell
266 and lymphocyte count. The trial was registered at ClinicalTrials.gov (NCT04331899). The
267 study was performed as an investigator initiated clinical trial with the FDA (IND 419217), and
268 approved by the Institutional Review Board of Stanford University.

269

270 *Recruitment and Enrolment*

271 Participants were recruited with flyers, online advertising, and phone calls to Stanford patients
272 with positive SARS-CoV-2 RT-PCR. Recruitment materials and phone calls were provided in
273 multiple languages, including English and Spanish. After confirming eligibility and providing
274 informed consent in the patient's primary language, participants underwent a standardized
275 history and physical exam, and completed bloodwork. If inclusion criteria were met, participants
276 were randomly assigned to Lambda or placebo using a 1:1 REDCAP-based computer-generated
277 randomization scheme that stratified by age (≥ 50 and < 50 years old) and sex. A password-
278 protected electronic spreadsheet containing the randomization allocation, along with the code

279 used to generate the allocation and seed used in the random number generation, was stored on
280 secure servers at Stanford.

281

282 *Study drug administration*

283 Phase 2 studies established the optimal dose for virologic suppression and minimizing treatment-
284 related adverse events (mainly aminotransferase and/or bilirubin elevations) for hepatitis C at
285 180 mcg given subcutaneously²¹. This dose is also currently being used in hepatitis D trials, and
286 was provided by Eiger BioPharmaceuticals for use in this study. Those assigned to Lambda
287 received a single 180 mcg subcutaneous injection of study drug (0.45 mL volume), and those
288 assigned to placebo received a 0.45 mL subcutaneous injection of saline (prepared by the
289 Stanford Investigational Pharmacy). The study medication/placebo syringe was dispensed by the
290 Stanford Investigational Pharmacist and administered by a study nurse. Lambda and placebo
291 syringes were identically labeled but differed in the appearance of the needle hub. Since the
292 nurse administering the medication might see syringe differences, the study was not strictly
293 “double-blind” even though all participants and investigators were blinded to treatment arm.
294 Participants were monitored for adverse events for thirty minutes after injection.

295

296 *Participant Follow Up*

297 Participants completed a daily symptom questionnaire using REDCap Cloud version 1.5.
298 Participants also provided in-home measurements of temperature and oxygen saturation using
299 study-provided devices. In-person follow-up visits were conducted at Day 1, 3, 5, 7, 10, 14, 21,
300 and 28, with assessment of symptoms and vitals, and collection of oropharyngeal swabs (FLOQ

301 Swabs; Copan Diagnostics). Peripheral blood was also collected at Day 5 and 14 to assess for
302 safety events.

303

304 *Laboratory procedures*

305 Laboratory measurements were performed by trained study personnel using point-of-care CLIA-
306 waived devices or in the Stanford Health Care Clinical Laboratory. Oropharyngeal swabs were
307 tested for SARS-CoV-2 in the Stanford Clinical Virology Laboratory using an emergency use
308 authorized, laboratory-developed, RT-PCR.^{38,39 40} Centers for Disease Control and Prevention
309 guidelines identify oropharyngeal swabs as acceptable upper respiratory specimens to test for the
310 presence of SARS-CoV-2 RNA,²⁴ and detection of SARS-CoV-2 RNA swabs using
311 oropharyngeal swabs was analytically validated in the Stanford virology laboratory.

312

313 IgG antibody titers against the SARS-CoV-2 spike receptor binding domain (RBD) were
314 assessed at enrolment.²⁵ Briefly, heat inactivated serum samples at enrolment were diluted 5-fold
315 starting at 1:50 and IgG antibody titers against RBD determined by ELISA. Absorbance was
316 measured at 450nm (SPECTRAMax 250, Molecular Devices). Samples were considered
317 seropositive against RBD if their absorbance value was greater than the mean plus four standard
318 deviation (SD) of all negative controls (n=130).

319

320 *Data and Safety Monitoring*

321 Adverse events were assessed and graded for severity according to standardized criteria.²⁰ A
322 Data and Safety Monitoring Board (DSMB) was established and conducted an interim analysis
323 to review clinical trial progress, integrity, and safety data.

324

325 *Study Outcomes*

326 The primary outcome was time to first of two consecutive negative oropharyngeal tests for
327 SARS-CoV-2 by RT-PCR. Secondary outcomes included: 1) Time to alleviation of all
328 symptoms, defined as time until the first day when no symptoms were reported; 2) SARS-CoV-2
329 oropharyngeal viral RNA levels over time; 3) SARS-CoV-2 oropharyngeal viral RNA area under
330 the curve (AUC); and 4) Incidence of emergency department visits or hospitalizations within 28
331 days of initiation of treatment. Adverse events (AEs) and serious AEs (SAEs) were the primary
332 safety endpoints. For secondary outcomes utilizing oropharyngeal viral RNA levels, we used the
333 following conversion formula from cycle threshold values to copies/ml PBS:

334
335
$$10^{(-0.288 * Ct + 11.007)} \times 120$$

336

337 Exploratory outcomes included: 1) Time until sustained resolution of symptoms, defined as the
338 first day when no symptoms were reported for the duration of the study; 2) Progression of
339 disease, defined as admission to the emergency department, hospitalization, or worsening cough
340 or shortness of breath defined as an increase in severity of two points or more on a five-point
341 scale.

342

343 *Statistical Analysis*

344 Analyses were performed according to assigned randomization arm (intent-to-treat). Absolute
345 standardized differences are displayed to compare the distribution of baseline characteristics⁴¹.

346 All models were covariate-adjusted for the randomization strata of age group and sex. Unless
347 otherwise noted, all tests were two-sided and conducted at the 0.05 level of significance.

348 Analyses were performed in R version 4.0.2.⁴²

349

350 Primary analysis: Time until shedding cessation was compared between arms using a Cox
351 proportional hazards model covariate-adjusted for age and sex, with the final hypothesis test
352 conducted at the $\alpha = 0.04999$ level of significance to allow for an interim analysis. The
353 hazard ratio for shedding cessation was estimated, along with its 95% confidence interval.
354 Participants who dropped out prior to having two consecutive negative tests were censored at the
355 time of their last positive test or on Day 1 if no positive tests were observed. The proportional
356 hazards assumption was verified by examining the Schoenfeld residuals. Efron's approximation
357 was used to handle ties in the Cox proportional hazards model.

358

359 Secondary analysis: Time until resolution of symptoms was compared using a Cox proportional
360 hazards model. Hazard ratios and 95% confidence intervals were reported. Change in viral load
361 during follow-up was compared using a linear mixed-effects model with random intercepts for
362 participant. The AUC of viral load was compared using linear regression. Multiple
363 imputation using chained equations was used to impute missing viral load data prior to area
364 under the curve calculation. Five data sets were imputed, and imputed values calculated using
365 non-missing viral load on each of the 7 sample collection days, treatment arm, age, sex, and
366 whether or not a participant was hospitalized. Model estimates were pooled across the five
367 imputed datasets by computing the total variance over the repeated analyses.

368

369 Estimates for change in viral load and viral load AUC for lambda compared to placebo and
370 corresponding 95% confidence intervals for the linear models were reported. The incidence of
371 hospitalizations and emergency department visits was estimated for each arm, with 95%

372 confidence intervals. AEs were compared by arm using the Chi-squared test and Fisher's exact
373 test for SAEs.

374

375 A sensitivity analysis was performed for the primary endpoint using only symptomatic patients
376 at baseline. Because two participants, after randomization, inadvertently were injected with the
377 incorrect syringe, we also conducted an as-treated analysis according to treatment actually
378 received.

379

380 A statistical interaction term between treatment arm and symptomatic status at baseline was
381 added to the Cox proportional hazards model adjusted for age group and sex to test whether
382 symptomatic status was an effect modifier of the relationship between treatment and time to
383 shedding cessation. The main effect of each potential effect modifier was also included in the
384 model. Additional effect modifiers specified a priori were 1) having a CT value < 30 (vs ≥ 30)
385 on baseline oropharyngeal swab, 2) IgG seropositivity at baseline, and 3) number of risk factors
386 or predictors for severe disease present at baseline (temperature ≥ 99.5 , cough, or shortness of
387 breath present at randomization [symptoms count as a single risk factor], age ≥ 60 , male sex,
388 Black race, Hispanic ethnicity, body mass index ≥ 30 , and lab values of baseline lymphocyte
389 counts < 1000 and baseline ALT ≥ 94). Effect modification was considered significant if the P
390 value for interaction was < 0.05 .

391 Post hoc analyses were conducted to test for differences in both median duration of symptoms
392 pre-randomization and baseline \log_{10} viral load between seronegative and seropositive
393 participants. The Kruskal-Wallis rank sum was used to test for differences in symptom duration
394 while a two-sample t-test was used to test for differences in \log_{10} viral load.

395 *Sample Size Determination*

396 Assuming 1:1 randomization and the use of a two-sided log rank test at the $\alpha=0.04999$ level
397 of significance for the final analysis, we anticipated the occurrence of 79 shedding cessation
398 events, which provided 80% power to detect a hazard ratio of 2.03. We additionally assumed
399 median time to shedding cessation of 14 days in the control arm and 7 days in the treatment arm,
400 a two-month accrual period, a two-week follow-up period after randomization of the last patient,
401 and 10% drop out in the control arm. This enabled an interim analysis conducted at
402 $\alpha=0.00001$ to assess overwhelming efficacy after 50% of participants completed 24 hours of
403 follow-up. We estimated that the total sample size required to achieve 79 events was 120 (60
404 participants per arm).

405

406 *Ethical approval*

407 The study was registered as an investigator initiated clinical trial with the FDA (IND 419217),
408 and approved by the Institutional Review Board of Stanford University. Written informed
409 consent was provided by all study participants.

410

411 *Role of the funding source*

412 The study was funded by anonymous donors to Stanford University, and Lambda provided by
413 Eiger BioPharmaceuticals. The funders had no role in data collection and analysis or the decision
414 to publish.

415

416

417 **Acknowledgements**

418 We thank all study participants who participated in this study, and the study team for their
419 tireless work. We also thank our colleagues at Stanford University Occupational Health and at
420 San Mateo Medical Center for participant referrals. Support from Stanford's Innovation
421 Medicine Accelerator and from Stanford ChEM-H is acknowledged. The Stanford REDCap
422 platform (<http://redcap.stanford.edu>) is developed and operated by Stanford Medicine Research
423 IT team. The REDCap platform services at Stanford are subsidized by a) Stanford School of
424 Medicine Research Office, and b) the National Center for Research Resources and the National
425 Center for Advancing Translational Sciences, National Institutes of Health, through grant UL1
426 TR001085.

427

428 **Authors' Contributions**

429 PJ, JA, JP, and US designed the study. PJ, JA, HB, KJ, SK, CV, OQ, KF, DW, JN, KE, CB, TW,
430 BA, JP, and US collected data. CL, HH, JP, VB developed study data instruments. CH, IC
431 provided study drug and guidance on study protocol. HH, NP, VB, and MD analyzed the data.
432 All authors participated in data interpretation. KJ and PJ wrote the first draft and writing the
433 manuscript and agreed on the decision to publish. There were no confidentiality agreements
434 between the sponsors and authors.

435

436 **Data Availability Statement**

437 The datasets generated and analyzed during the current study will be made available in the
438 Stanford Digital Repository (lane.stanford.edu) at the time of publication.

439

440 **Declaration of Competing Interests**

441 Colin Hislop and Ingrid Choong are scientists at Eiger BioPharmaceuticals, Inc., which provided
442 the Interferon Lambda used for this study. Jeffrey Glenn serves on the board of Eiger
443 BioPharmaceuticals, Inc. Colin Hislop and Ingrid Choong own stock and options of Eiger
444 BioPharmaceuticals, Inc. Jeffrey Glenn has an equity interest in Eiger BioPharmaceuticals, Inc.
445 Jeffrey Glenn and Ingrid Choong are inventors on a pending patent application relating to the use
446 of interferon lambda for coronavirus. Eiger BioPharmaceuticals played no role in study design,
447 conduct of the study, or analysis of the data.

448 References

- 449 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at
450 Johns Hopkins University (JHU). (Johns Hopkins University).
- 451 2. Baud, D., *et al.* Real estimates of mortality following COVID-19 infection. *Lancet Infect*
452 *Dis* **20**, 773 (2020).
- 453 3. Park, A. & Iwasaki, A. Type I and Type III Interferons - Induction, Signaling, Evasion,
454 and Application to Combat COVID-19. *Cell Host Microbe* **27**, 870-878 (2020).
- 455 4. Kotenko, S.V. IFN-lambdas. *Curr Opin Immunol* **23**, 583-590 (2011).
- 456 5. Zhou, Z., *et al.* Type III interferon (IFN) induces a type I IFN-like response in a restricted
457 subset of cells through signaling pathways involving both the Jak-STAT pathway and the
458 mitogen-activated protein kinases. *J Virol* **81**, 7749-7758 (2007).
- 459 6. Lazear, H.M., Schoggins, J.W. & Diamond, M.S. Shared and Distinct Functions of Type
460 I and Type III Interferons. *Immunity* **50**, 907-923 (2019).
- 461 7. Yuen, C.K., *et al.* SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent
462 interferon antagonists. *Emerg Microbes Infect* **9**, 1418-1428 (2020).
- 463 8. Chu, H., *et al.* Comparative replication and immune activation profiles of SARS-CoV-2
464 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis
465 of COVID-19. *Clin Infect Dis* (2020).
- 466 9. Arunachalam, P.S., *et al.* Systems biological assessment of immunity to mild versus
467 severe COVID-19 infection in humans. *Science* **369**, 1210-1220 (2020).
- 468 10. Hadjadj, J., *et al.* Impaired type I interferon activity and inflammatory responses in
469 severe COVID-19 patients. *Science* **369**, 718-724 (2020).
- 470 11. Felgenhauer, U., *et al.* Inhibition of SARS-CoV-2 by type I and type III interferons. *J*
471 *Biol Chem* (2020).
- 472 12. Dinno, K.H., *et al.* A mouse-adapted model of SARS-CoV-2 to test COVID-19
473 countermeasures. *Nature* (2020).
- 474 13. Zhou, Q., *et al.* Interferon-alpha2b Treatment for COVID-19. *Front Immunol* **11**, 1061
475 (2020).
- 476 14. Hung, I.F., *et al.* Triple combination of interferon beta-1b, lopinavir-ritonavir, and
477 ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label,
478 randomised, phase 2 trial. *Lancet* **395**, 1695-1704 (2020).
- 479 15. COVID-19 – SG016 Clinical Trial Data Readout. Vol. 2020 (synairgen.com, 2020).
- 480 16. Mordstein, M., *et al.* Lambda interferon renders epithelial cells of the respiratory and
481 gastrointestinal tracts resistant to viral infections. *J Virol* **84**, 5670-5677 (2010).
- 482 17. Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-lambda (IFN-lambda) is
483 expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo.
484 *PLoS Pathog* **4**, e1000017 (2008).
- 485 18. Pagliaccetti, N.E., Chu, E.N., Bolen, C.R., Kleinstein, S.H. & Robek, M.D. Lambda and
486 alpha interferons inhibit hepatitis B virus replication through a common molecular
487 mechanism but with different in vivo activities. *Virology* **401**, 197-206 (2010).
- 488 19. Robek, M.D., Boyd, B.S. & Chisari, F.V. Lambda interferon inhibits hepatitis B and C
489 virus replication. *J Virol* **79**, 3851-3854 (2005).
- 490 20. Davidson, S., *et al.* IFNlambda is a potent anti-influenza therapeutic without the
491 inflammatory side effects of IFNalpha treatment. *EMBO Mol Med* **8**, 1099-1112 (2016).

- 492 21. Muir, A.J., *et al.* A randomized phase 2b study of peginterferon lambda-1a for the
493 treatment of chronic HCV infection. *J Hepatol* **61**, 1238-1246 (2014).
- 494 22. O'Brien, T.R., *et al.* Weak Induction of Interferon Expression by Severe Acute
495 Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-lambda to
496 Treat Early Coronavirus Disease 2019. *Clin Infect Dis* **71**, 1410-1412 (2020).
- 497 23. Prokunina-Olsson, L., *et al.* COVID-19 and emerging viral infections: The case for
498 interferon lambda. *J Exp Med* **217**(2020).
- 499 24. Centers for Disease Control and Prevention. CDC 2019-nCoV Real-Time RT-PCR
500 Diagnostic Panel instructions for use (effective February 4, 2020).
501 <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html>.
- 502 25. Chakraborty, S., *et al.* Proinflammatory IgG Fc structures in patients with severe
503 COVID-19. *Nat Immunol* (2020).
- 504 26. Chan, H.L.Y., *et al.* Peginterferon lambda for the treatment of HBeAg-positive chronic
505 hepatitis B: A randomized phase 2b study (LIRA-B). *J Hepatol* **64**, 1011-1019 (2016).
- 506 27. Major, J., *et al.* Type I and III interferons disrupt lung epithelial repair during recovery
507 from viral infection. *Science* **369**, 712-717 (2020).
- 508 28. Broggi, A., *et al.* Type III interferons disrupt the lung epithelial barrier upon viral
509 recognition. *Science* **369**, 706-712 (2020).
- 510 29. Monk, P.D., *et al.* Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001)
511 for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled,
512 phase 2 trial. *The Lancet Respiratory Medicine*.
- 513 30. Zhang, Q., *et al.* Inborn errors of type I IFN immunity in patients with life-threatening
514 COVID-19. *Science* **370**(2020).
- 515 31. Bastard, P., *et al.* Autoantibodies against type I IFNs in patients with life-threatening
516 COVID-19. *Science* **370**(2020).
- 517 32. Center, C.o.S.C.E.O. Santa Clara County COVID-19 Demographics Dashboard. Vol.
518 2020.
- 519 33. Price-Haywood, E.G., Burton, J., Fort, D. & Seoane, L. Hospitalization and Mortality
520 among Black Patients and White Patients with Covid-19. *N Engl J Med* **382**, 2534-2543
521 (2020).
- 522 34. Stokes, E.K., *et al.* Coronavirus Disease 2019 Case Surveillance - United States, January
523 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep* **69**, 759-765 (2020).
- 524 35. Chastain, D.B., *et al.* Racial Disproportionality in Covid Clinical Trials. *N Engl J Med*
525 **383**, e59 (2020).
- 526 36. Chowkwanyun, M. & Reed, A.L., Jr. Racial Health Disparities and Covid-19 - Caution
527 and Context. *N Engl J Med* **383**, 201-203 (2020).
- 528 37. Regeneron Pharmaceuticals Inc. [https://investor.regeneron.com/news-releases/news-
529 release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and](https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and).
- 530 38. Hogan, C.A., Sahoo, M.K. & Pinsky, B.A. Sample Pooling as a Strategy to Detect
531 Community Transmission of SARS-CoV-2. *JAMA* (2020).
- 532 39. Hogan, C.A., *et al.* Comparison of the Panther Fusion and a Laboratory-developed Test
533 Targeting the Envelope gene for Detection of SARS-CoV-2. *Journal of Clinical*
534 *Virology*, 104383 (2020).
- 535 40. Corman, V.M., *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-
536 PCR. *Euro Surveill* **25**(2020).

- 537 41. Austin, P.C. Using the Standardized Difference to Compare the Prevalence of a Binary
538 Variable Between Two Groups in Observational Research. *Communications in Statistics*
539 *- Simulation and Computation* **38**, 1228-1234 (2009).
- 540 42. Team, R.C. R: A language and environment for statistical computing. R Foundation for
541 Statistical Computing. (Vienna, Austria, 2019).
542

543 **FIGURE LEGENDS**

544

545 **Figure 1.** CONSORT Diagram

546

547 **Figure 2.** Kaplan-Meier Analyses of the Primary and Key Secondary Outcome in the Intention-

548 to-Treat Population. (A) Time until cessation of SARS-CoV-2 viral shedding from

549 oropharyngeal swabs stratified by treatment arm, Lambda (blue) vs. placebo (red). (B) Time

550 until resolution of all symptoms stratified by treatment arm, Lambda (blue) vs. placebo (red)

551

552 **Figure 3.** Kaplan-Meier Analyses of the Primary Outcome, Stratified by Baseline Seropositivity

553 and Viral Load. (A) Time until cessation of SARS-CoV-2 viral shedding from oropharyngeal

554 swabs stratified by baseline SARS-CoV-2 seropositivity, seropositive (dashed) and seronegative

555 (solid), and treatment arm, Lambda (blue) vs. placebo (red). (B) Time until cessation of SARS-

556 CoV-2 viral shedding from oropharyngeal swabs stratified by baseline SARS-CoV-2

557 oropharyngeal virus CT value, CT value ≥ 30 (dashed) and CT value < 30 (solid), and treatment

558 arm, Lambda (blue) vs. placebo (red).

559

560 **Figure 4.** Alanine transaminase levels measured at day 0 and day 5 and 14 post-randomization in

561 Placebo (red) and Lambda (blue) arms.

562

563

564

565

566

567 **Table 1. Baseline characteristics of study participants**

568

	Treatment arm			ASD
	Lambda (N=60)	Placebo (N=60)	Overall (N=120)	
Age in years , median (range)	37 (18-66)	34 (20-71)	36 (18-71)	0.14
Female , n (%)	24 (40.0%)	26 (43.3%)	50 (41.7%)	0.07
Race / Ethnicity , n (%)				0.46
Latinx	34 (56.7%)	41 (68.3%)	75 (62.5%)	
White	18 (30.0%)	15 (25.0%)	33 (27.5%)	
Asian	3 (5.0%)	4 (6.7%)	7 (5.8%)	
Native Hawaiian or other Pacific Islander	2 (3.3%)	0 (0%)	2 (1.7%)	
Unknown	2 (3.3%)	0 (0%)	2 (1.7%)	
More than one race	1 (1.7%)	0 (0%)	1 (0.8%)	
BMI (kg/m²) , median (IQR)	27.6 (25.4-31.1)	28.5 (24.8-32.3)	27.7 (24.9-32.0)	0.06
Asymptomatic at baseline , n (%)	6 (10.0%)	2 (3.3%)	8 (6.7%)	0.27
Duration of symptoms in days prior to randomization , median (IQR) ¹	4 (3-6)	5 (3-5)	5 (3-6)	0.13
Symptoms at baseline , n (%)				
Fatigue	33 □(55%)	42 □(70%)	75 □(62.5%)	0.25
Cough	33 (55.0%)	36 (60.0%)	69 (57.5%)	0.08
Headache	29 □(48.3%)	36 □(60%)	65 □(54.2%)	0.22
Myalgias	29 □(48.3%)	34 □(56.7%)	63 □(52.5%)	0.15
Decreased taste or smell	25 □(41.7%)	32 □(53.3%)	57 □(47.5%)	0.22
Chills	22 □(36.7%)	27 □(45%)	49 □(40.8%)	0.16
Sore throat	22 □(36.7%)	23 □(38.3%)	45 □(37.5%)	0.04
Joint pain	19 □(31.7%)	19 □(31.7%)	38 □(31.7%)	<0.001
Diarrhea	16 □(26.7%)	18 □(30%)	34 □(28.3%)	0.06
Nausea	11 □(18.3%)	23 □(38.3%)	34 □(28.3%)	0.44
Shortness of breath	16 (26.7%)	16 (26.7%)	32 (26.7%)	0.01
Chest pain/pressure	14 □(23.3%)	13 □(21.7%)	27 □(22.5%)	0.05
Runny nose	10 □(16.7%)	16 □(26.7%)	26 □(21.7%)	0.23
Abdominal pain	7 □(11.7%)	7 □(11.7%)	14 □(11.7%)	<0.001
Rash	4 □(6.7%)	5 □(8.3%)	9 □(7.5%)	0.06

	Treatment arm			ASD
	Lambda (N=60)	Placebo (N=60)	Overall (N=120)	
Vomiting	1 □ (1.7%)	5 □ (8.3%)	6 □ (5%)	0.31
Vital signs at enrollment				
Temperature 99.5F+, n (%)	6 (10.0%)	7 (11.7%)	13 (10.8%)	0.05
Oxygen saturation, median (IQR)	98 (2.5)	99 (3)	98 (3)	
Baseline laboratory values, median (IQR)				
White blood cell (WBC) count, cells/μl	5.5 (4.3-6.8)	5.6 (4.0-7.5)	5.5 (4.1-7.1)	0.08
Absolute lymphocyte count (ALC), cells/μl	1.5 (1.2-1.9)	1.5 (1.2-2.3)	1.5 (1.2-2.2)	0.14
Aspartate aminotransferase, IU/L	31 (26-41)	30 (25-39.3)	30 (25-41)	0.25
Alanine aminotransferase, IU/L	32.5 (21-52.3)	30.5 (23-47.5)	31.5 (22-50.3)	0.25
Baseline oropharyngeal SARS-CoV-2 cycle threshold, median (IQR)²	30.9 (26.4-33.8)	29.3 (26.4-34.3)	30.3 (26.4-34.3)	0.12
Baseline Log10 Viral Load, median (IQR)²	4.2 (3.3 - 5.5)	4.7 (3.2 - 5.5)	4.4 (3.2 - 5.5)	0.12
Baseline SARS-CoV-2 IgG seropositivity, n (%)	21 (35.0%)	28 (46.7%)	49 (40.8%)	0.24
Sum of risk factors, median (IQR)	3 (2-3)	3 (2-4)	3 (2-3)	0.07

569 IQR = inner quartile range; ASD = absolute standardized difference. sum of risk factors is defined as the number of
570 relevant severe disease risk factors present at baseline (presence of either temperature of 99.5F+, cough, or shortness of
571 breath; age 60+; male sex; Black race; Latinx ethnicity; BMI 30+; ALC<1000; ALT 94+).

572 among n=103 participant who reported symptoms prior to randomization (n=48 in lambda and n=55 in placebo).

573 among n=87 participants with detectable OP virus (n=44 in lambda and n=43 in placebo).

574

575 **Table 2. Efficacy and Safety Outcomes**

	Treatment arm	
	Lambda (n=60)	Placebo (n=60)
Primary efficacy outcome		
Duration until viral shedding cessation in days, median (95% CI)	7 (5-13)	7 (5-10)
Secondary efficacy outcomes		
Duration until resolution of symptoms in days, median (95% CI)	8 (6-11)	9 (5-11)
Hospitalizations by Day 28, n participants (%)	2 (3.3%)	2 (3.3%)
Emergency Department visits by Day 28, n participants (%)	5 (8.3%)	3 (5%)
Log Oropharyngeal viral load over time, mean change at day 14 (SD)	-4.3 (4.3)	-4.9 (4.7)
Log ₁₀ viral load area under the curve through day 14, median (IQR)	28.5 (20.1)	29.6 (19.0)
Exploratory efficacy outcomes		
Duration until sustained symptom resolution in days, median (95% CI)	20 (16-27)	20 (17-24)
Duration until respiratory symptom resolution in days, median (95% CI)	6 (4-7)	4 (2-7)
Duration until systemic and respiratory symptom resolution in days, median (95% CI)	8 (6-11)	5.5 (5-10)
Duration until disease progression in days, median among those who progress* (IQR)	5 (1)	2 (1)
Safety Outcomes		
Serious adverse events, n (%)	2 (3.3%)	2 (3.3%)
Number of adverse events, n	36	30
Participants with adverse events, n (%)	25 (41.7%)	21 (35.0%)
LFT-related adverse events, n	16	5
Participants with LFT-related adverse events, n (%)	15 (25.0%)	5 (8.3%)

576 IQR = inner quartile range; aHR = adjusted hazard ratio (adjusted for age 50+ and sex), aHR >1 favors faster shedding


577 cessation in Lambda vs. placebo arms; aHR <1 favors delayed shedding cessation in Lambda vs. placebo arms.

578 AUC = area under the curve

579 Number of participants that progressed – 10 in Lambda, 7 in placebo


580

581 **Figure 1.**





582
583
584
585
586
587
588
589
590
591
592

593 **Figure 2**
594



595
596
597
598
599 **Figure 3.**

600



601
602
603
604

605 **Figure 4.**

